Regulators Test Remedies, Separations Become Operating Programs, and Carve-Outs Close Through Sequenced Filings

AkzoNobel and MMG Show Regulators Are Testing Remedies in Practice

On 6 November 2026, the European Commission cleared AkzoNobel’s merger with Axalta only after forcing a full divestiture of AkzoNobel’s EEA vehicle-refinish coatings business, including manufacturing capacity, brands, assets, IP, employees, transitional services, and an EU-approved buyer overseen by a trustee. At the same time, Brussels extended its Phase II review of MMG’s nickel deal from 30 November to 21 December 2026 to test a proposed supply guarantee against concerns over concentrated low-carbon ferronickel supply and possible diversion away from Europe.

The shift is that regulators are no longer just demanding a remedy; they are stress-testing whether it can actually work in market. That makes the AkzoNobel package a useful marker for where clearance is heading: the fix has to be complete, operationally credible, and executable on a regulator’s timetable, while the MMG extension shows even supply commitments can be held open until Brussels is satisfied they will hold up in practice. For deal teams, this is the next step in the same execution problem: remedy planning can no longer be an afterthought or a legal cleanup exercise, because buyer readiness, transition mechanics, and operational separation now need to be built into the transaction from the start.

CVS, Siemens Healthineers, and Kraft Heinz Push Separation Into the Operating Model

CVS set a 1H28 tax-free separation of its retail pharmacy business into two public companies, with intercompany agreements expected to keep commercial ties in place for 15–18 months. Siemens Healthineers is pushing the same logic deeper, carving out diagnostics into Olyrian Diagnostics by mid-2028 with full separation of R&D, sales and branding, legal entities, and support infrastructure. Kraft Heinz’s $650 million sale of Maxwell House and other North American coffee brands to One Rock, while retaining 30%, shows the playbook now includes hybrid monetization, not just spin or sell. Coming after the recent focus on debt, tax, and regulatory setup, this week’s shift is toward how much operating separation has to be built before any transaction can close. For corporate development teams, the job is moving further upstream: parallel structure scenarios, TSA and stranded-cost design, and standalone boundary decisions now have to be worked through before the deal path is fixed.

Carve-Outs Now Close Through Sequenced Regulatory Workstreams

Nestlé and Platinum Equity moved their 50:50 joint venture, Peranel, closer to closing after Pakistan’s Competition Commission approved the deal in Phase I with no remedies or conditions, following the European Commission’s non-opposition on 12 October 2026, also without remedies. Announced on 23 July 2026, the transaction packages Nestlé’s global waters and premium beverages business into a standalone platform, including S.Pellegrino, Perrier, Acqua Panna, Nestlé Pure Life, and related local water operations. Closing still depends on employee-consultation processes and other regulatory approvals, with completion expected in the first half of 2027.

For Corporate Development, this is a clean carve-out playbook: approvals are being sequenced across jurisdictions, while separation work continues in parallel. Nestlé is not fully exiting; it is retaining 50% ownership, which makes governance design, TSA planning, and post-signing coordination as important as valuation. The practical lesson for your team is that execution risk now sits in regulatory tracking, legal and HR alignment, and readiness for close. People who can manage those workstreams from signing through final clearance become more valuable to the deal and to the function.